Semaglutide (Ozempic) for Kidney Disease: What FLOW Showed

TL;DR: The FLOW trial, published in 2024, showed that semaglutide, the drug in Ozempic, protects the kidneys in people with type 2 diabetes and chronic kidney disease. It lowered the risk of a composite of kidney failure and kidney or cardiovascular death by about 24%, and it also reduced cardiovascular events and overall deaths, results so strong that the trial was stopped early. On that basis, the FDA added a kidney indication to Ozempic in January 2025, making it the first GLP-1 drug proven to protect the kidney. It joins SGLT2 inhibitors and finerenone, on top of a foundation blood-pressure medicine, as the layered tools for diabetic kidney disease, each working through a different mechanism. The benefit is proven in diabetic kidney disease specifically, and it slows the decline rather than reversing it.

Can a diabetes drug protect the kidneys?

Semaglutide became famous for lowering blood sugar and driving weight loss. Its newer story is the kidney. For people with type 2 diabetes, the kidneys are among the organs most at risk: diabetic kidney disease is a leading cause of kidney failure. The question the FLOW trial set out to answer was whether semaglutide, beyond managing blood sugar and weight, could slow that damage directly. The answer was yes, and clearly enough that regulators added kidney protection to the drug's label.

In January 2025, the FDA approved Ozempic to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. It is the first and so far only GLP-1 drug to carry a kidney indication, a meaningful addition for a population at high risk of both kidney and heart disease.

What did the FLOW trial show?

FLOW enrolled about 3,500 adults who had both type 2 diabetes and chronic kidney disease, and gave them weekly semaglutide at the 1.0 mg dose or a placebo, on top of their standard care, for a median of about 3.4 years.¹ The main measure combined the outcomes that matter most in kidney disease: kidney failure, a sustained large drop in kidney function, and death from kidney or cardiovascular causes.

Semaglutide lowered the risk of that combined outcome by about 24%. The benefit was strong and consistent enough that an independent monitoring board recommended stopping the trial early, once the evidence was clear. Beyond the kidney, semaglutide also lowered major cardiovascular events by about 18% and death from any cause by about 20%, and it slowed the yearly decline in kidney function. For a group facing two of the most feared complications of diabetes, that is a substantial across-the-board benefit.

How does semaglutide protect the kidney?

This is an interesting question, because the answer appears to be more than the obvious. The obvious explanation is that semaglutide helps the kidney indirectly, by lowering blood sugar, reducing weight, and lowering blood pressure, all of which ease the strain on the kidneys. Those effects are genuine and matter.

But they do not tell the whole story. When researchers analyzed FLOW to see how much of the kidney benefit came from weight loss, the answer was almost none; the protection appeared largely independent of the pounds lost. That points to semaglutide having more direct effects on the kidney itself, likely calming inflammation, improving blood flow within the kidney, and reducing the protein leak that marks kidney damage. These direct effects are plausible and partly shown in laboratory work, though not fully proven in people. The fair picture is a drug that protects the kidney through several routes at once, some obvious and some still being mapped.

How does it fit with SGLT2 inhibitors and finerenone?

Modern care for diabetic kidney disease has become a layered defense, and semaglutide is the newest layer. The foundation is a blood-pressure medicine that protects the kidney, an ACE inhibitor or ARB. On top of that sit three newer classes, each proven to lower risk through a different mechanism: SGLT2 inhibitors, the nonsteroidal drug finerenone, and now GLP-1 drugs like semaglutide. Together they form a set of complementary tools rather than competing ones.

A fair question is whether stacking these drugs adds up. Because they work through different mechanisms, the logic of combining them is sound, and it is increasingly common in practice. But the proof is still incomplete. In FLOW, only about 15% of participants were also on an SGLT2 inhibitor, too few to firmly establish the added benefit of the combination, and that small group did not show a clear extra gain. So the grounded position is that semaglutide's benefit held up regardless of whether people were on an SGLT2 inhibitor, which is reassuring, but that the combination rests more on complementary mechanisms than on a dedicated trial proving it adds kidney protection. That trial has not been done.

Who is it for, and what are the limits?

The evidence is specific, and the specificity matters. FLOW studied people with type 2 diabetes and established chronic kidney disease, and that is who the kidney benefit is proven for. It is not established for kidney disease in people without diabetes; a small, short study hinted at benefit there, but it measured a marker rather than hard outcomes and was far too small to prove anything. And it is not a general kidney treatment for everyone with kidney trouble. Semaglutide slows the progression of diabetic kidney disease and lowers the risk of kidney failure; it does not treat or reverse kidney damage that has already occurred.

Side effects

The side effects are the familiar GLP-1 effects, centered on the gut: nausea, vomiting, and diarrhea, usually mildest when the dose is raised slowly. Because heavy vomiting or diarrhea can dehydrate a person and briefly stress the kidneys, staying hydrated matters, and the drug is sometimes paused around acute illness. Like others in its class, it carries a boxed warning about a rare thyroid tumor seen in rodents, so it is avoided in people with a personal or family history of medullary thyroid cancer or the MEN2 syndrome, along with cautions about pancreatitis and gallbladder problems. The thyroid warning comes from animal studies, and whether it applies to people is unknown.

Guidance from the Clinic

"For my patients with diabetes and failing kidneys, FLOW was one of the most welcome results in years, because it added a third proven tool to a fight we used to have fewer weapons for. My approach now is to think in layers: the blood-pressure medicine as the base, then an SGLT2 inhibitor, finerenone, and semaglutide, chosen and stacked based on the person in front of me. What I keep clear is what the drug does and does not do. It slows the decline and lowers the risk of kidney failure and cardiovascular death, which is enormous, but it does not reverse kidney damage already done, and its proof is in diabetic kidney disease rather than every kidney problem. The bonus that makes it special is that the same weekly shot helps the kidney, the heart, and the weight all at once, which for this high-risk group is a rare kind of leverage."

Related at Fishtown Medicine

• SGLT2 Inhibitors: Heart, Kidney, and Longevity - the companion pillar of cardio-renal protection
• Finerenone (Kerendia) - the nonsteroidal drug that protects the diabetic kidney
• Ozempic vs Metformin - where semaglutide fits among metabolic drugs
• Metabolic Health and Insulin Resistance - the root driver of diabetic complications
• What Is a Preventive Cardiologist? - the decision layer around organ-protective drugs
• Cystatin C and Kidney Function for Longevity - the biomarkers that catch kidney trouble early

Scientific References

1. Perkovic V, Tuttle KR, Rossing P, et al. "Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes." New England Journal of Medicine. 2024;391(2):109-121.